Related Experiment Video
Updated: Mar 26, 2026
05:18
Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
Published on: January 16, 2026
138
The future of left ventricular assist devices
1Division of Cardiac Surgery, Department of Surgery, The Ohio State University Wexner Medical Center; Columbus, OH, USA.
Journal of Thoracic Disease
|January 22, 2016
Summary
Left ventricular assist device (LVAD) implantation is revolutionizing heart failure treatment. Improved technology and patient selection enhance survival and reduce adverse events for advanced heart failure patients.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Heart failure is a significant global health challenge.
- Left ventricular assist devices (LVADs) represent a critical therapeutic advancement.
- Traditional treatments for end-stage heart failure have limitations.
Purpose of the Study:
- To highlight the impact of left ventricular assist device (LVAD) implantation on end-stage heart failure treatment.
- To discuss the advancements in LVAD technology and patient selection.
- To underscore the evolving role of LVADs in managing heart failure.
Main Methods:
- Review of current literature on LVADs in heart failure.
- Analysis of technological advancements in LVAD devices.
- Evaluation of patient selection criteria and outcomes.
Main Results:
- LVAD implantation has transformed end-stage heart failure management.
- Technological progress has improved survival rates.
- Enhanced patient selection has reduced the adverse event profile of LVADs.
Conclusions:
- LVADs are a pivotal therapeutic option for heart failure patients.
- Continued understanding of heart failure will further refine LVAD therapy.
- LVADs offer a promising future in the treatment of advanced heart failure.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
621
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
621
01:22Heart Failure VI: Adjunct Therapies
543
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
543
01:30Heart Failure V: Medical Management
517
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
517
01:30Cardiomyopathy II: Dilated Cardiomyopathy
744
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
744
01:26Heart Failure Drugs: Inotropic Agents
1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
01:29Heart Failure II: Pathophysiology
1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K